• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ascendis Pharma ADR (NQ: ASND )

    138.44 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 138.44
    Bid (Size) 55.38 (2)
    Ask (Size) 220.11 (1)
    Prev. Close 138.44
    Today's Range 138.44 - 138.44
    52wk Range 76.02 - 161.00
    Shares Outstanding 57,152,295
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Looking Into Ascendis Pharma's Recent Short Interest
    Via Benzinga
    $1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
    Via Benzinga

    Performance

    YTD
    +8.55%
    +8.55%
    1 Month
    -8.91%
    -8.91%
    3 Month
    +7.15%
    +7.15%
    6 Month
    +55.01%
    +55.01%
    1 Year
    +59.60%
    +59.60%

    More News

    Read More
    Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
    Via Talk Markets
    Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
    Via Benzinga
    Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
    Via Benzinga
    5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
    Via Talk Markets
    $1000 Invested In This Stock 15 Years Ago Would Be Worth $45,000 Today
    Via Benzinga
    How Is The Market Feeling About Ascendis Pharma?
    Via Benzinga
    If You Invested $1000 In This Stock 10 Years Ago, You Would Have $70,000 Today
    Via Benzinga
    These Five Small-Cap Stocks Under The Radar Are Expected To Surge, Says Stock Researcher
    Via Benzinga
    Earnings Scheduled For February 7, 2024
    Via Benzinga
    Ascendis Pharma's Earnings: A Preview
    Via Benzinga
    $100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth This Much Today
    Via Benzinga
    Ascendis Pharma's Growth Hormone Deficiency Candidate Outperforms in Phase 3 Trial
    Via Benzinga
    Analyst Expectations for Ascendis Pharma's Future
    Via Benzinga
    Recap: Ascendis Pharma Q3 Earnings
    Via Benzinga
    Preview: Ascendis Pharma's Earnings
    Via Benzinga
    The Latest Analyst Ratings for Ascendis Pharma
    Via Benzinga
    The Latest Analyst Ratings for Ascendis Pharma
    Via Benzinga
    Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty
    Via Benzinga
    Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
    From Royalty Pharma plc
    Via GlobeNewswire
    Earnings Scheduled For September 5, 2023
    Via Benzinga
    Earnings Preview For Ascendis Pharma
    Via Benzinga
    Analyst Expectations for Ascendis Pharma's Future
    Via Benzinga
    Bragar Eagel & Squire, P.C. Is Investigating Ascendis, Alvotech, Shift4, and Waldencast and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.